DZ1889A1 - Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number: DZ1889A1
Authority: DZ; Algeria
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; quinoline derivatives; new quinoline
Prior art date: 1994-05-27

Application number

DZ950061A

Other languages

English (en)

Original Assignee

Smithkline Beecham Farma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-27

Filing date

1995-05-24

Publication date

2002-02-17

1994-05-27 Priority claimed from IT94MI001099A external-priority patent/ITMI941099A1/it

1995-03-14 Priority claimed from ITMI950494 external-priority patent/IT1293558B1/it

1995-05-24 Application filed by Smithkline Beecham Farma filed Critical Smithkline Beecham Farma

2002-02-17 Application granted granted Critical

2002-02-17 Publication of DZ1889A1 publication Critical patent/DZ1889A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

DZ950061A 1994-05-27 1995-05-24 Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ1889A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT94MI001099A ITMI941099A1 (it)	1994-05-27	1994-05-27	Derivati chinolinici
ITMI950494 IT1293558B1 (it)	1995-03-14	1995-03-14	Derivati chinolinici

Publications (1)

Publication Number	Publication Date
DZ1889A1 true DZ1889A1 (fr)	2002-02-17

Family

ID=26331143

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ950061A DZ1889A1 (fr)	1994-05-27	1995-05-24	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (35)

Country	Link
US (5)	US5811553A (fr)
EP (2)	EP0940391B1 (fr)
JP (5)	JP3664492B2 (fr)
KR (1)	KR100316571B1 (fr)
CN (3)	CN1092642C (fr)
AP (1)	AP578A (fr)
AR (1)	AR037069A2 (fr)
AT (2)	ATE246677T1 (fr)
AU (1)	AU699319B2 (fr)
BG (2)	BG64004B1 (fr)
BR (1)	BR9507788A (fr)
CA (1)	CA2191352C (fr)
CZ (1)	CZ291476B6 (fr)
DE (2)	DE69533408T2 (fr)
DK (1)	DK0804419T3 (fr)
DZ (1)	DZ1889A1 (fr)
ES (2)	ES2227769T3 (fr)
FI (2)	FI115052B (fr)
HK (2)	HK1003884A1 (fr)
HU (1)	HU226535B1 (fr)
IL (1)	IL113844A (fr)
MA (1)	MA23560A1 (fr)
MX (1)	MX9605903A (fr)
MY (1)	MY129596A (fr)
NO (2)	NO307783B1 (fr)
NZ (1)	NZ287442A (fr)
OA (1)	OA10592A (fr)
PL (2)	PL186075B1 (fr)
PT (2)	PT940391E (fr)
RO (1)	RO114445B1 (fr)
SA (1)	SA95160290B1 (fr)
SK (2)	SK282722B6 (fr)
TW (2)	TW427977B (fr)
UA (1)	UA51623C2 (fr)
WO (1)	WO1995032948A1 (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK282722B6 (sk) *	1994-05-27	2002-11-06	Smithkline Beecham S.P.A.	N-(alfa-Etylbenzyl)-3-hydroxy-2-fenylchinolín-4-karboxamid, farmaceutický prípravok s jeho obsahom a jeho použitie
GB9524104D0 (en) *	1995-11-24	1996-01-24	Smithkline Beecham Spa	Novel compounds
AU757836B2 (en) *	1995-11-24	2003-03-06	Smithkline Beecham Spa	Quinoline derivatives
TR199800924T2 (xx) *	1995-11-24	1998-08-21	Smithkline Beecham S.P.A.	Quinoline t�revleri.
AR004735A1 (es) *	1995-11-24	1999-03-10	Smithkline Beecham Spa	Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
GB9524137D0 (en)	1995-11-24	1996-01-24	Smithkline Beecham Spa	Novel compounds
CA2284035A1 (fr) *	1997-03-14	1998-09-24	Smithkline Beecham Corporation	Nouveaux quinoline- et naphthalenecarboxamides, compositions pharmaceutiques et procedes d'inhibition de la calpaine
US6077850A (en) *	1997-04-21	2000-06-20	G.D. Searle & Co.	Substituted benzopyran analogs for the treatment of inflammation
PL336942A1 (en) *	1997-05-23	2000-07-17	Smithkline Beecham Spa	Derivatives of quinoline-4-carboxamide as antagonists of nk-2 and nk-3 receptor
US20010012846A1 (en) *	1997-05-23	2001-08-09	Glardina Giuseppe Arnaldo Maria	Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
EP1652840A3 (fr) *	1997-09-17	2006-05-17	Smithkline Beecham Corporation	(-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
AP1201A (en) *	1997-09-17	2003-09-01	Smithkline Beecham Corp	Method for the synthesis of quinoline derivatives.
US6083944A (en) *	1997-10-07	2000-07-04	Cephalon, Inc.	Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
KR20010075726A (ko) *	1998-11-20	2001-08-09	파올로 비지, 엔리꼬 카쭐라니	Ｎｋ-3 및 ｎｋ-2 수용체 길항제로서의퀴놀린-4-카르복스아미드 유도체
GB9825554D0 (en) *	1998-11-20	1999-01-13	Smithkline Beecham Spa	Novel Compounds
US6780875B2 (en) *	1998-11-20	2004-08-24	Smithkline Beecham S.P.A.	Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
DE60018707T2 (de) *	1999-01-25	2006-02-09	Smithkline Beecham Corp.	Anti-androgene und verfahren zur behandlung von krankheiten
US7037922B1 (en) *	2000-03-10	2006-05-02	Neurogen Corporation	Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
JP2002540203A (ja)	1999-03-29	2002-11-26	ニューロゲンコーポレイション	Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
AU4802500A (en)	1999-04-26	2000-11-10	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6521618B2 (en)	2000-03-28	2003-02-18	Wyeth	3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AU2001276556A1 (en) *	2000-08-11	2002-02-25	Smithkline Beecham P.L.C.	Novel pharmaceutical use of quinnoline derivatives
GB0028964D0 (en) *	2000-11-28	2001-01-10	Smithkline Beecham Spa	Novel compounds
US6540733B2 (en) *	2000-12-29	2003-04-01	Corazon Technologies, Inc.	Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
WO2002083664A1 (fr) *	2001-04-11	2002-10-24	Glaxosmithkline S.P.A.	Derives de 3-substitue quinoline-4-carboxamide utilises comme antagonistes du recepteur nk3 et du recepteur nk2
US20040152727A1 (en) *	2001-05-18	2004-08-05	Hay Douglas William Pierre	Novel use
EP1541149A1 (fr) *	2002-06-26	2005-06-15	Kyowa Hakko Kogyo Co., Ltd.	Inhibiteur de phosphodiesterase
GB0228287D0 (en) *	2002-12-04	2003-01-08	Smithkline Beecham Corp	Chemical compounds
GB0228288D0 (en) *	2002-12-04	2003-01-08	Smithkline Beecham Corp	Chemical compounds
GB0312609D0 (en)	2003-06-02	2003-07-09	Astrazeneca Ab	Novel compounds
SE0302139D0 (sv) *	2003-07-28	2003-07-28	Astrazeneca Ab	Novel compounds
ATE440866T1 (de)	2003-12-22	2009-09-15	Glaxo Group Ltd	Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
CA2555133A1 (fr)	2004-02-04	2005-09-01	Pfizer Products Inc.	Composes de quinoline substitues
JP2007530591A (ja) *	2004-03-25	2007-11-01	スミスクライン・ビーチャム・コーポレイション	双極性障害を治療するための、ｎｋ３アンタゴニストの使用
TW200602055A (en) *	2004-03-30	2006-01-16	Smithkline Beecham Corp	Spray dried pharmaceutical compositions
US7495103B2 (en)	2004-06-24	2009-02-24	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US8354427B2 (en)	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
GB0417560D0 (en) *	2004-08-06	2004-09-08	Merck Sharp & Dohme	Therapeutic compounds
GB0417559D0 (en) *	2004-08-06	2004-09-08	Merck Sharp & Dohme	Therapeutic compounds
GB0425077D0 (en) *	2004-11-12	2004-12-15	Smithkline Beecham Corp	Novel compounds
GB0425076D0 (en) *	2004-11-12	2004-12-15	Smithkline Beecham Corp	Novel compounds
GB0425075D0 (en) *	2004-11-12	2004-12-15	Smithkline Beecham Corp	Novel compounds
GB0428233D0 (en) *	2004-12-23	2005-01-26	Glaxo Group Ltd	Compounds
CA2611060A1 (fr) *	2005-06-03	2006-12-07	R. Thomas Simpson	Derives de quinoline utilises comme antagonistes de nk3
WO2006137789A1 (fr) *	2005-06-23	2006-12-28	Astrazeneca Ab	Esters de quinoline-3-sulfonate en tant que régulateurs de récepteurs nk3
GB0515580D0 (en)	2005-07-29	2005-09-07	Merck Sharp & Dohme	Therapeutic compounds
EP1919871A4 (fr) *	2005-08-02	2010-08-18	Glaxosmithkline Llc	Procédé pour la synthèse de dérivés de la quinoline
JP2009504642A (ja) *	2005-08-11	2009-02-05	アストラゼネカ・アクチエボラーグ	Ｎｋ−３受容体の調節剤としてのオキソピリジルキノリンアミド
JP2009504640A (ja) *	2005-08-11	2009-02-05	アストラゼネカ・アクチエボラーグ	Ｎｋ−３受容体の調節剤としてのアミドアルキルピリジルキノリン
WO2007035156A1 (fr) *	2005-09-21	2007-03-29	Astrazeneca Ab	Quinoline-4-carboxamides n-oxo-hétérocycliques et n-oxo-alkyliques en tant que ligands de récepteur nk-3
AR058051A1 (es) *	2005-09-21	2008-01-23	Astrazeneca Ab	Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
AR057130A1 (es) *	2005-09-21	2007-11-14	Astrazeneca Ab	Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW201018662A (en) *	2005-12-12	2010-05-16	Astrazeneca Ab	Alkylsulphonamide quinolines
GB0525662D0 (en)	2005-12-16	2006-01-25	Glaxo Group Ltd	Immunoglobulins
US20090105272A1 (en) *	2005-12-24	2009-04-23	Grootenhuis Peter D J	Prodrugs of modulators of ABC transporters
PT1993360T (pt)	2005-12-28	2017-05-25	Vertex Pharma	Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
CN101410392A (zh) *	2006-01-27	2009-04-15	阿斯利康(瑞典)有限公司	酰胺取代的喹啉类化合物
GB0603087D0 (en) *	2006-02-15	2006-03-29	Glaxo Group Ltd	Novel use
BRPI0809106A2 (pt)	2007-03-22	2014-08-26	Astrazeneca Ab	Derivados de quinolina para o tratamento de doenças inflamatórias
WO2008131779A1 (fr) *	2007-04-26	2008-11-06	H. Lundbeck A/S	Dérivés d'isoquinolinone utilisés en tant qu'antagonistes de nk3
US8173639B2 (en)	2007-04-26	2012-05-08	H. Lundbeck A/S	Isoquinolinone derivatives as NK3 antagonists
BRPI0816239A2 (pt) *	2007-08-22	2015-02-24	Allergan Inc	Derivados terapêuticos de quinolina e naftaleno
WO2009049791A2 (fr) *	2007-10-15	2009-04-23	F. Hoffmann-La Roche Ag	Antagoniste du récepteur nk3 radiomarqué
PE20091036A1 (es)	2007-11-30	2009-08-15	Astrazeneca Ab	Derivado de quinolina como antagonista del receptor p2x7
NZ590154A (en)	2008-06-23	2012-05-25	Lundbeck & Co As H	Isoquinolinone derivatives as nk3 antagonists
US8242134B2 (en)	2008-09-15	2012-08-14	H. Lundbeck A/S	Isoquinolinone derivatives as NK3 antagonists
WO2010045948A1 (fr)	2008-10-20	2010-04-29	H. Lundbeck A/S	Dérivés d’isoquinolinone comme antagonistes du nk3
NZ624460A (en)	2009-03-20	2015-12-24	Vertex Pharma	Process for making modulators of cystic fibrosis transmembrane conductance regulator
TW201143768A (en)	2009-12-15	2011-12-16	Lundbeck & Co As H	Pyridone derivatives as NK3 antagonists
TW201144311A (en)	2010-03-12	2011-12-16	Lundbeck & Co As H	Azaisoquionolinone derivatives as NK3 antagonists
US8487102B2 (en) *	2010-04-20	2013-07-16	Hoffmann-La Roche Inc.	Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8802700B2 (en)	2010-12-10	2014-08-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
US9346814B2 (en)	2012-01-17	2016-05-24	Universiteit Antwerp	FAP inhibitors
MX2014010253A (es)	2012-02-27	2014-11-12	Vertex Pharma	Composicion farmaceutica y administraciones de la misma.
CN102702099A (zh) *	2012-06-21	2012-10-03	江苏恩华药业股份有限公司	(s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法
CA2909752A1 (fr)	2013-04-19	2014-10-23	Astrazeneca Ab	Compose antagoniste du recepteur nk3 (nk3ra) utilise dans une methode pour traiter le syndrome des ovaires polykystiques (sopk)
EP3160469B1 (fr)	2014-06-25	2021-04-28	Emory University	Procédés de gestion d'une peur conditionnée à l'aide d'antagonistes du récepteur de la neurokinine
WO2016004035A1 (fr) *	2014-07-01	2016-01-07	Icahn School Of Medicine At Mount Sinai	Dérivés 2-aryl-4-quinoléinecarboxamide pour le traitement de maladies de la thyroïde
WO2016037954A1 (fr)	2014-09-09	2016-03-17	Bayer Pharma Aktiengesellschaft	N,2-diarylquinoline-4-carboxamides substitués et utilisation desdits n,2-diarylquinoline-4-carboxamides substitués comme anti-inflammatoires
US9701639B2 (en)	2014-10-07	2017-07-11	Vertex Pharmaceuticals Incorporated	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016146602A1 (fr)	2015-03-18	2016-09-22	Bayer Pharma Aktiengesellschaft	N-bicyclo-2-arylchinolino-4-carboxamides substitués et leur utilisation
PL3297631T3 (pl) *	2015-05-18	2020-03-31	Nerre Therapeutics Limited	Antagoniści receptora NK-1/NK-3 do leczenia uderzeń gorąca
WO2017072629A1 (fr)	2015-10-29	2017-05-04	Cadila Healthcare Limited	Combinaison pharmaceutique d'antagoniste du récepteur nk3 et de biguanides
WO2017153231A1 (fr)	2016-03-09	2017-09-14	Bayer Pharma Aktiengesellschaft	N-cyclo-2-arylisochinolinon-4-carboxamides substitués et leur utilisation
WO2017153235A1 (fr)	2016-03-09	2017-09-14	Bayer Pharma Aktiengesellschaft	N-cyclo-3-aryl-1-naphthamides substitués et leur utilisation
WO2017153234A1 (fr)	2016-03-09	2017-09-14	Bayer Pharma Aktiengesellschaft	N-cyclo-2-arylchinolin-4-carboxamides substitués et leur utilisation
CN105884626B (zh) *	2016-05-04	2017-10-20	龙曦宁（上海）医药科技有限公司	一种2‑氨基茚满衍生物的合成方法及其产品
EP3609869A1 (fr)	2017-04-10	2020-02-19	Bayer Aktiengesellschaft	N-aryléthyl-2-arylquinoléine-4-carboxamides substitués et leur utilisation
TWI770157B (zh) *	2017-04-10	2022-07-11	德商拜耳廠股份有限公司	經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
WO2019090001A1 (fr)	2017-11-02	2019-05-09	California Institute Of Technology	Antagonistes de la neurokinine et utilisations associées
US20210401821A1 (en) *	2018-11-15	2021-12-30	Kyushu University, National University Corporation	Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1560489A (en) *	1976-05-21	1980-02-06	Fisons Ltd	Pharmaceutical compositions
FR2538388B1 (fr)	1982-12-24	1985-06-21	Pharmuka Lab	Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
DE3905339A1 (de)	1989-02-22	1990-09-06	Basf Ag	Chinolin-4-carbonsaeurederivate und deren verwendung
US5037835A (en) *	1989-10-24	1991-08-06	Hoechst-Roussel Pharmaceuticals Inc.	Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US4992448A (en) *	1989-10-24	1991-02-12	Hoechst-Roussel Pharmaceuticals Inc.	Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
DE69126058T2 (de) *	1990-03-26	1997-09-25	Matsushita Electric Ind Co Ltd	Lichtempfindliches Material für Elektrophotographie
ATE161530T1 (de) *	1992-09-04	1998-01-15	Takeda Chemical Industries Ltd	Kondensierte heterozyklische verbindungen, deren herstellung und verwendung
US5434158A (en) *	1994-04-26	1995-07-18	Merck & Co., Inc.	Spiro-substituted azacycles as neurokinin-3 antagonists
SK282722B6 (sk)	1994-05-27	2002-11-06	Smithkline Beecham S.P.A.	N-(alfa-Etylbenzyl)-3-hydroxy-2-fenylchinolín-4-karboxamid, farmaceutický prípravok s jeho obsahom a jeho použitie
US5607936A (en) *	1994-09-30	1997-03-04	Merck & Co., Inc.	Substituted aryl piperazines as neurokinin antagonists

1995
- 1995-05-23 SK SK47-99A patent/SK282722B6/sk not_active IP Right Cessation
- 1995-05-23 ES ES98204483T patent/ES2227769T3/es not_active Expired - Lifetime
- 1995-05-23 PT PT98204483T patent/PT940391E/pt unknown
- 1995-05-23 CA CA002191352A patent/CA2191352C/fr not_active Expired - Fee Related
- 1995-05-23 PT PT95920894T patent/PT804419E/pt unknown
- 1995-05-23 PL PL95317381A patent/PL186075B1/pl not_active IP Right Cessation
- 1995-05-23 UA UA96124918A patent/UA51623C2/uk unknown
- 1995-05-23 DE DE69533408T patent/DE69533408T2/de not_active Expired - Lifetime
- 1995-05-23 BR BR9507788A patent/BR9507788A/pt not_active IP Right Cessation
- 1995-05-23 EP EP98204483A patent/EP0940391B1/fr not_active Expired - Lifetime
- 1995-05-23 RO RO96-02234A patent/RO114445B1/ro unknown
- 1995-05-23 WO PCT/EP1995/002000 patent/WO1995032948A1/fr active IP Right Grant
- 1995-05-23 PL PL95341889A patent/PL186665B1/pl not_active IP Right Cessation
- 1995-05-23 ES ES95920894T patent/ES2204952T3/es not_active Expired - Lifetime
- 1995-05-23 AU AU26164/95A patent/AU699319B2/en not_active Ceased
- 1995-05-23 JP JP50028796A patent/JP3664492B2/ja not_active Expired - Fee Related
- 1995-05-23 NZ NZ287442A patent/NZ287442A/en not_active IP Right Cessation
- 1995-05-23 AT AT95920894T patent/ATE246677T1/de not_active IP Right Cessation
- 1995-05-23 CN CN95194338A patent/CN1092642C/zh not_active Expired - Fee Related
- 1995-05-23 AT AT98204483T patent/ATE273959T1/de not_active IP Right Cessation
- 1995-05-23 DE DE69531458T patent/DE69531458T2/de not_active Expired - Lifetime
- 1995-05-23 DK DK95920894T patent/DK0804419T3/da active
- 1995-05-23 CZ CZ19963470A patent/CZ291476B6/cs not_active IP Right Cessation
- 1995-05-23 KR KR1019960706701A patent/KR100316571B1/ko not_active IP Right Cessation
- 1995-05-23 HU HU9603262A patent/HU226535B1/hu not_active IP Right Cessation
- 1995-05-23 EP EP95920894A patent/EP0804419B1/fr not_active Expired - Lifetime
- 1995-05-23 SK SK1514-96A patent/SK282721B6/sk not_active IP Right Cessation
- 1995-05-24 AP APAP/P/1995/000745A patent/AP578A/en active
- 1995-05-24 DZ DZ950061A patent/DZ1889A1/fr active
- 1995-05-25 US US08/450,438 patent/US5811553A/en not_active Expired - Lifetime
- 1995-05-25 MA MA23898A patent/MA23560A1/fr unknown
- 1995-05-25 US US08/450,437 patent/US6608083B1/en not_active Expired - Fee Related
- 1995-05-25 MY MYPI95001381A patent/MY129596A/en unknown
- 1995-05-25 IL IL11384495A patent/IL113844A/xx not_active IP Right Cessation
- 1995-05-26 TW TW084105319A patent/TW427977B/zh not_active IP Right Cessation
- 1995-05-26 TW TW088121625A patent/TW533199B/zh not_active IP Right Cessation
- 1995-10-03 SA SA95160290A patent/SA95160290B1/ar unknown
1996
- 1996-11-25 BG BG101008A patent/BG64004B1/bg unknown
- 1996-11-26 NO NO965036A patent/NO307783B1/no unknown
- 1996-11-26 MX MX9605903A patent/MX9605903A/es not_active IP Right Cessation
- 1996-11-26 FI FI964712A patent/FI115052B/fi active IP Right Grant
- 1996-11-27 OA OA60928A patent/OA10592A/en unknown
1998
- 1998-04-09 HK HK98103021A patent/HK1003884A1/xx not_active IP Right Cessation
1999
- 1999-01-15 CN CN99100978A patent/CN1276211A/zh active Pending
- 1999-02-10 FI FI990268A patent/FI119721B/fi active IP Right Grant
- 1999-02-16 BG BG103181A patent/BG103181A/bg unknown
- 1999-04-16 NO NO991813A patent/NO326714B1/no unknown
- 1999-06-18 JP JP11172597A patent/JP2000026314A/ja active Pending
2000
- 2000-03-06 HK HK00101401A patent/HK1024469A1/xx not_active IP Right Cessation
- 2000-06-22 AR ARP000103117A patent/AR037069A2/es unknown
2001
- 2001-05-29 US US09/867,133 patent/US20030236281A1/en not_active Abandoned
- 2001-10-24 JP JP2001326622A patent/JP2002179594A/ja active Pending
2002
- 2002-03-18 CN CN02107941A patent/CN1428145A/zh active Pending
2004
- 2004-09-30 JP JP2004287629A patent/JP2005068155A/ja active Pending
- 2004-11-29 US US10/999,180 patent/US20050096316A1/en not_active Abandoned
2006
- 2006-03-21 US US11/385,461 patent/US7482458B2/en not_active Expired - Fee Related
- 2006-12-28 JP JP2006355694A patent/JP2007126475A/ja not_active Ceased

Also Published As

Publication number	Publication date
CN1428145A (zh)	2003-07-09
NO991813D0 (no)	1999-04-16
MY129596A (en)	2007-04-30
CZ347096A3 (en)	1997-10-15
SK282721B6 (sk)	2002-11-06
DE69531458T2 (de)	2004-08-05
CA2191352C (fr)	2001-01-30
EP0804419B1 (fr)	2003-08-06
SK151496A3 (en)	1997-07-09
AU699319B2 (en)	1998-12-03
BG64004B1 (bg)	2003-09-30
PL317381A1 (en)	1997-04-01
FI990268A0 (fi)	1999-02-10
US5811553A (en)	1998-09-22
AU2616495A (en)	1995-12-21
IL113844A (en)	2005-05-17
HK1024469A1 (en)	2000-10-13
JP2000026314A (ja)	2000-01-25
JP2007126475A (ja)	2007-05-24
HU226535B1 (en)	2009-03-30
DE69533408D1 (de)	2004-09-23
US20050096316A1 (en)	2005-05-05
PL186665B1 (pl)	2004-02-27
CN1276211A (zh)	2000-12-13
DE69531458D1 (de)	2003-09-11
DK0804419T3 (da)	2003-11-24
TW533199B (en)	2003-05-21
WO1995032948A1 (fr)	1995-12-07
TW427977B (en)	2001-04-01
JP3664492B2 (ja)	2005-06-29
ES2204952T3 (es)	2004-05-01
US20030236281A1 (en)	2003-12-25
KR100316571B1 (ko)	2002-05-30
UA51623C2 (uk)	2002-12-16
EP0804419A1 (fr)	1997-11-05
DE69533408T2 (de)	2005-09-08
FI964712A (fi)	1997-01-23
CN1092642C (zh)	2002-10-16
EP0940391A2 (fr)	1999-09-08
AP9500745A0 (en)	1995-07-31
AP578A (en)	1997-03-26
ATE273959T1 (de)	2004-09-15
FI990268A (fi)	1999-02-10
EP0940391A3 (fr)	1999-11-10
EP0940391B1 (fr)	2004-08-18
CN1156451A (zh)	1997-08-06
MX9605903A (es)	1998-08-30
SK282722B6 (sk)	2002-11-06
US7482458B2 (en)	2009-01-27
NO991813L (no)	1997-01-24
BG103181A (bg)	1999-09-30
NO307783B1 (no)	2000-05-29
NO965036L (no)	1997-01-24
JP2005068155A (ja)	2005-03-17
NO326714B1 (no)	2009-02-02
JP2002179594A (ja)	2002-06-26
OA10592A (en)	2002-08-27
HU9603262D0 (en)	1997-01-28
FI964712A0 (fi)	1996-11-26
BR9507788A (pt)	1997-09-23
ATE246677T1 (de)	2003-08-15
CA2191352A1 (fr)	1995-12-07
NO965036D0 (no)	1996-11-26
AR037069A2 (es)	2004-10-20
RO114445B1 (ro)	1999-04-30
IL113844A0 (en)	1995-08-31
SA95160290A (ar)	2005-12-03
PT804419E (pt)	2003-12-31
SK4799A3 (en)	1999-06-11
HK1003884A1 (en)	1998-11-13
US20060160846A1 (en)	2006-07-20
NZ287442A (en)	1998-05-27
US6608083B1 (en)	2003-08-19
HUT76286A (en)	1997-07-28
SA95160290B1 (ar)	2006-06-21
ES2227769T3 (es)	2005-04-01
JPH10500697A (ja)	1998-01-20
MA23560A1 (fr)	1995-12-31
FI119721B (fi)	2009-02-27
CZ291476B6 (cs)	2003-03-12
BG101008A (en)	1997-08-29
PL186075B1 (pl)	2003-10-31
PT940391E (pt)	2004-12-31
FI115052B (fi)	2005-02-28

Publication	Publication Date	Title
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2303A1 (fr)	2002-12-28	Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2227A1 (fr)	2002-12-25	Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
DZ2634A1 (fr)	2003-03-08	Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
CY2537B1 (fr)	2006-06-28	Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3042A1 (fr)	2004-03-27	Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr)	2002-12-02	Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2962A1 (fr)	2004-03-15	Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ3009A1 (fr)	2004-03-27	Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr)	2004-03-27	Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2394A1 (fr)	2003-06-04	Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2188A1 (fr)	2002-12-02	Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.